Efficacy of PI3K inhibitors in advanced breast cancer.
PI3K inhibitors
breast cancer
targeted therapy
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
entrez:
21
12
2019
pubmed:
21
12
2019
medline:
26
6
2020
Statut:
ppublish
Résumé
The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration and deregulated apoptosis. Its activation has been linked to endocrine resistance and worse prognosis in certain subgroups of breast cancer. In addition, deregulation of the PI3K/Akt pathway including PIK3CA activating mutation is frequently present in breast cancer. Multiple efforts have been carried out to target this pathway, initially with pan-PI3K inhibitors with some hint of activity but hampered by their limiting side-effects. A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant. The specificity of alpelisib against the p110α catalytic isoform provided additional efficacy and a better toxicity profile. In this review, we summarize the main research with PI3K inhibitors in breast cancer and we provide some insight of potential future combinations of this treatment in breast cancer patients.
Identifiants
pubmed: 31859349
pii: 5681700
doi: 10.1093/annonc/mdz381
pmc: PMC6923787
doi:
Substances chimiques
Phosphoinositide-3 Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
x12-x20Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Références
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
J Med Chem. 2013 Jun 13;56(11):4597-610
pubmed: 23662903
Nature. 2007 Jul 26;448(7152):439-44
pubmed: 17611497
Nat Rev Clin Oncol. 2019 Jul;16(7):425-441
pubmed: 30914826
Int J Cancer. 1995 Aug 22;64(4):280-5
pubmed: 7657393
Onco Targets Ther. 2018 Aug 13;11:4817-4827
pubmed: 30147333
Ann Oncol. 2017 Jun 1;28(6):1167-1168
pubmed: 28505221
Ann Oncol. 2016 Aug;27(8):1519-25
pubmed: 27177864
Ann Oncol. 2020 Mar;31(3):377-386
pubmed: 32067679
Clin Cancer Res. 2016 Apr 1;22(7):1583-91
pubmed: 26563128
J Cell Sci. 2000 Jan;113 Pt 2:207-14
pubmed: 10633072
Ann Oncol. 2016 Aug;27(8):1443-8
pubmed: 27143638
Trends Cell Biol. 2018 Nov;28(11):911-925
pubmed: 30061045
Mol Cancer Ther. 2014 May;13(5):1021-31
pubmed: 24748656
Nature. 2000 Sep 28;407(6803):538-41
pubmed: 11029009
Clin Cancer Res. 2009 Aug 15;15(16):5049-59
pubmed: 19671852
Mol Cancer Ther. 2012 Feb;11(2):317-28
pubmed: 22188813
Breast Cancer Res Treat. 2018 Apr;168(2):357-364
pubmed: 29198055
Science. 1997 Mar 28;275(5308):1943-7
pubmed: 9072974
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Cancer Discov. 2012 Nov;2(11):1048-63
pubmed: 22915751
Ann Oncol. 2016 Nov;27(11):2059-2066
pubmed: 27573562
Clin Cancer Res. 2015 Jan 1;21(1):77-86
pubmed: 25370471
Nature. 2008 May 29;453(7195):662-6
pubmed: 18449193
Eur J Cancer. 2017 Nov;86:28-36
pubmed: 28950146
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
JAMA Oncol. 2019 Feb 1;5(2):e184475
pubmed: 30543347
J Med Chem. 2008 Sep 25;51(18):5522-32
pubmed: 18754654
Breast Cancer Res Treat. 2018 Sep;171(2):371-381
pubmed: 29850984
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
J Clin Oncol. 2014 Apr 20;32(12):1202-9
pubmed: 24663045
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Br J Cancer. 2013 Apr 30;108(8):1587-92
pubmed: 23579222
Breast Cancer Res Treat. 2010 Jan;119(2):379-90
pubmed: 19844788
Trends Biochem Sci. 2005 Apr;30(4):194-204
pubmed: 15817396
Ann Oncol. 2019 Jul 1;30(7):1051-1060
pubmed: 31050709
Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
pubmed: 20379207
JAMA Oncol. 2016 Nov 01;2(11):1477-1486
pubmed: 27367583
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14372-7
pubmed: 23940356
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
Cancer Treat Rev. 2016 Apr;45:87-96
pubmed: 26995633
J Clin Invest. 2010 Jul;120(7):2406-13
pubmed: 20530877
Cancer Discov. 2017 Jul;7(7):704-715
pubmed: 28331003
Ann Oncol. 2012 Aug;23(8):2034-2042
pubmed: 22172323
Ann Oncol. 2017 Feb 1;28(2):313-320
pubmed: 27803006
Nature. 2015 Feb 12;518(7538):240-4
pubmed: 25409150
Nature. 2008 Aug 7;454(7205):776-9
pubmed: 18594509
Cancer Res. 2008 Aug 1;68(15):6084-91
pubmed: 18676830
Clin Cancer Res. 2012 Jun 15;18(12):3462-9
pubmed: 22421194
Clin Cancer Res. 2015 Apr 1;21(7):1525-9
pubmed: 25645861
J Clin Oncol. 2014 Nov 20;32(33):3753-61
pubmed: 25332247
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Onco Targets Ther. 2014 Apr 10;7:543-52
pubmed: 24748804
Cancer Cell. 2014 Jul 14;26(1):136-49
pubmed: 25002028
Nat Rev Immunol. 2003 Apr;3(4):317-30
pubmed: 12669022
Sci Signal. 2008 Sep 09;1(36):ra3
pubmed: 18780892
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Pharmaceuticals (Basel). 2019 May 06;12(2):
pubmed: 31064155
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
J Clin Oncol. 2018 May 1;36(13):1291-1299
pubmed: 29401002
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Mol Cancer Ther. 2014 May;13(5):1117-29
pubmed: 24608574
Cancer Treat Rev. 2017 Dec;61:53-60
pubmed: 29100169
Clin Cancer Res. 2016 Aug 1;22(15):3755-63
pubmed: 26920887
Cell Metab. 2010 Mar 3;11(3):220-30
pubmed: 20197055
Int J Cancer. 2010 Mar 1;126(5):1121-31
pubmed: 19685490
J Clin Oncol. 2014 Apr 1;32(10):1050-7
pubmed: 24590635
Lancet Oncol. 2019 Sep;20(9):1226-1238
pubmed: 31402321
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4330-5
pubmed: 9113989
Lancet Oncol. 2016 Jun;17(6):811-821
pubmed: 27155741
Cancer Res. 2005 Apr 1;65(7):2554-9
pubmed: 15805248
Sci Rep. 2014 Sep 01;4:6255
pubmed: 25176561
Nature. 2006 May 18;441(7091):366-70
pubmed: 16625210
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745
Clin Cancer Res. 2019 May 15;25(10):2975-2987
pubmed: 30723140
Nat Med. 2005 May;11(5):507-14
pubmed: 15834429
Eur J Cancer. 2017 Nov;85:133-145
pubmed: 28923573
Nat Rev Genet. 2006 Aug;7(8):606-19
pubmed: 16847462
Breast Cancer Res. 2011 Apr 21;13(2):R46
pubmed: 21510863